Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 255

1.

A variant in FTO gene shows association with histological ulceration in cutaneous melanoma.

Kalo E, Güvenç C, Marasigan V, Lambrechts D, van den Oord J, Garmyn M.

J Cutan Pathol. 2019 Aug 30. doi: 10.1111/cup.13575. [Epub ahead of print] No abstract available.

PMID:
31469442
2.

An updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for melanoma.

Cook MG, Massi D, Szumera-Ciećkiewicz A, Van den Oord J, Blokx W, van Kempen LC, Balamurugan T, Bosisio F, Koljenović S, Portelli F, van Akkooi ACJ; EORTC Melanoma Group.

Eur J Cancer. 2019 Jun;114:1-7. doi: 10.1016/j.ejca.2019.03.010. Epub 2019 Apr 17.

PMID:
31005015
3.

Melanoma susceptibility variant rs869330 in the MTAP gene is associated with melanoma outcome.

Marasigan V, Güvenç C, van den Oord JJ, Stas M, Boecxstaens V, Bechter O, Wolter P, Lambrechts D, Garmyn M.

Melanoma Res. 2019 Jan 23. doi: 10.1097/CMR.0000000000000578. [Epub ahead of print]

PMID:
30681428
4.

Genomic Landscape of Spitzoid Neoplasms Impacting Patient Management.

Hillen LM, Van den Oord J, Geybels MS, Becker JC, Zur Hausen A, Winnepenninckx V.

Front Med (Lausanne). 2018 Dec 13;5:344. doi: 10.3389/fmed.2018.00344. eCollection 2018. Review.

5.

Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.

Rogiers A, Thomas D, Vander Borght S, van den Oord JJ, Bechter O, Dewaele M, Rambow F, Marine JC, Wolter P.

Br J Dermatol. 2019 Feb;180(2):421-422. doi: 10.1111/bjd.17250. Epub 2018 Nov 22. No abstract available.

PMID:
30248172
6.

Targeting PDGF-mediated recruitment of pericytes blocks vascular mimicry and tumor growth.

Thijssen VL, Paulis YW, Nowak-Sliwinska P, Deumelandt KL, Hosaka K, Soetekouw PM, Cimpean AM, Raica M, Pauwels P, van den Oord JJ, Tjan-Heijnen VC, Hendrix MJ, Heldin CH, Cao Y, Griffioen AW.

J Pathol. 2018 Dec;246(4):447-458. doi: 10.1002/path.5152. Epub 2018 Oct 30.

7.

Molecular profiling of Spitz nevi identified by digital RNA counting.

Hillen LM, Geybels MS, Rennspiess D, Spassova I, Ritter C, Becker JC, Garmyn M, Zur Hausen A, Van den Oord J, Winnepenninckx V.

Melanoma Res. 2018 Dec;28(6):510-520. doi: 10.1097/CMR.0000000000000495.

8.

Toward Minimal Residual Disease-Directed Therapy in Melanoma.

Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, Karras P, Brown D, Chang YH, Debiec-Rychter M, Adriaens C, Radaelli E, Wolter P, Bechter O, Dummer R, Levesque M, Piris A, Frederick DT, Boland G, Flaherty KT, van den Oord J, Voet T, Aerts S, Lund AW, Marine JC.

Cell. 2018 Aug 9;174(4):843-855.e19. doi: 10.1016/j.cell.2018.06.025. Epub 2018 Jul 12.

9.

Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy.

Talebi A, Dehairs J, Rambow F, Rogiers A, Nittner D, Derua R, Vanderhoydonc F, Duarte JAG, Bosisio F, Van den Eynde K, Nys K, Pérez MV, Agostinis P, Waelkens E, Van den Oord J, Fendt SM, Marine JC, Swinnen JV.

Nat Commun. 2018 Jun 27;9(1):2500. doi: 10.1038/s41467-018-04664-0.

10.

Scleroderma-like cutaneous lesions during treatment with paclitaxel and gemcitabine in a patient with pancreatic adenocarcinoma. Review of literature.

Verhulst L, Noë E, Morren MA, Verslype C, Van Cutsem E, Van den Oord JJ, De Haes P.

Int J Dermatol. 2018 Sep;57(9):1075-1079. doi: 10.1111/ijd.14067. Epub 2018 Jun 25. Review.

PMID:
29938783
11.

Mouse Cutaneous Melanoma Induced by Mutant BRaf Arises from Expansion and Dedifferentiation of Mature Pigmented Melanocytes.

Köhler C, Nittner D, Rambow F, Radaelli E, Stanchi F, Vandamme N, Baggiolini A, Sommer L, Berx G, van den Oord JJ, Gerhardt H, Blanpain C, Marine JC.

Cell Stem Cell. 2017 Nov 2;21(5):679-693.e6. doi: 10.1016/j.stem.2017.08.003. Epub 2017 Oct 12.

12.

SCENIC: single-cell regulatory network inference and clustering.

Aibar S, González-Blas CB, Moerman T, Huynh-Thu VA, Imrichova H, Hulselmans G, Rambow F, Marine JC, Geurts P, Aerts J, van den Oord J, Atak ZK, Wouters J, Aerts S.

Nat Methods. 2017 Nov;14(11):1083-1086. doi: 10.1038/nmeth.4463. Epub 2017 Oct 9.

13.

Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE.

Rogiers A, Vander Borght S, Tuand K, Wolter P, Stas M, Boecxstaens V, Garmyn M, van den Oord JJ, Vandenberghe P, Bechter O.

Melanoma Res. 2017 Oct;27(5):507-510. doi: 10.1097/CMR.0000000000000376.

PMID:
28800030
14.

New insights into naevoid melanomas: a clinicopathological reassessment.

Cook MG, Massi D, Blokx WAM, Van den Oord J, Koljenović S, De Giorgi V, Kissin E, Grant M, Mandal A, Gremel G, Gaudy C, Viros A, Dhomen N, Khosrotehrani K, Marais R, Green AC, Mihm MC Jr.

Histopathology. 2017 Dec;71(6):943-950. doi: 10.1111/his.13317. Epub 2017 Oct 2.

PMID:
28741688
15.

Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma.

Wouters J, Vizoso M, Martinez-Cardus A, Carmona FJ, Govaere O, Laguna T, Joseph J, Dynoodt P, Aura C, Foth M, Cloots R, van den Hurk K, Balint B, Murphy IG, McDermott EW, Sheahan K, Jirström K, Nodin B, Mallya-Udupi G, van den Oord JJ, Gallagher WM, Esteller M.

BMC Med. 2017 Jun 5;15(1):101. doi: 10.1186/s12916-017-0851-3.

16.

Immunohistochemical Profiling of Corneas With Fuchs Endothelial Corneal Dystrophy.

De Roo AK, Janssens T, Foets B, van den Oord JJ.

Cornea. 2017 Jul;36(7):866-874. doi: 10.1097/ICO.0000000000001212.

PMID:
28481834
17.

Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma.

Olvedy M, Tisserand JC, Luciani F, Boeckx B, Wouters J, Lopez S, Rambow F, Aibar S, Thienpont B, Barra J, Köhler C, Radaelli E, Tartare-Deckert S, Aerts S, Dubreuil P, van den Oord JJ, Lambrechts D, De Sepulveda P, Marine JC.

J Clin Invest. 2017 Jun 1;127(6):2310-2325. doi: 10.1172/JCI91291. Epub 2017 May 2.

18.

The effect of L-PRF membranes on bone healing in rabbit tibiae bone defects: micro-CT and biomarker results.

Faot F, Deprez S, Vandamme K, Camargos GV, Pinto N, Wouters J, van den Oord J, Quirynen M, Duyck J.

Sci Rep. 2017 Apr 12;7:46452. doi: 10.1038/srep46452.

19.

Molecular genetic and immunotherapeutic targets in metastatic melanoma.

Melis C, Rogiers A, Bechter O, van den Oord JJ.

Virchows Arch. 2017 Aug;471(2):281-293. doi: 10.1007/s00428-017-2113-3. Epub 2017 Mar 29. Review.

PMID:
28357489
20.

Identification of a novel species of papillomavirus in giraffe lesions using nanopore sequencing.

Vanmechelen B, Bertelsen MF, Rector A, Van den Oord JJ, Laenen L, Vergote V, Maes P.

Vet Microbiol. 2017 Mar;201:26-31. doi: 10.1016/j.vetmic.2016.12.035. Epub 2016 Dec 30.

PMID:
28284619
21.

Identification of Circulating Fibrocytes and Dendritic Derivatives in Corneal Endothelium of Patients With Fuchs' Dystrophy.

De Roo AK, Wouters J, Govaere O, Foets B, van den Oord JJ.

Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):670-681. doi: 10.1167/iovs.16-20880.

PMID:
28135362
22.

Immunoplasticity in cutaneous melanoma: beyond pure morphology.

Bosisio FM, van den Oord JJ.

Virchows Arch. 2017 Apr;470(4):357-369. doi: 10.1007/s00428-016-2058-y. Epub 2017 Jan 5. Review. No abstract available.

PMID:
28054151
23.

The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene.

van Kempen LC, Redpath M, Elchebly M, Klein KO, Papadakis AI, Wilmott JS, Scolyer RA, Edqvist PH, Pontén F, Schadendorf D, van Rijk AF, Michiels S, Dumay A, Helbling-Leclerc A, Dessen P, Wouters J, Stass M, Greenwood CM, Ghanem GE, van den Oord J, Feunteun J, Spatz A.

Sci Transl Med. 2016 Dec 14;8(369):369ra177.

PMID:
27974665
24.

p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity.

Adriaens C, Standaert L, Barra J, Latil M, Verfaillie A, Kalev P, Boeckx B, Wijnhoven PW, Radaelli E, Vermi W, Leucci E, Lapouge G, Beck B, van den Oord J, Nakagawa S, Hirose T, Sablina AA, Lambrechts D, Aerts S, Blanpain C, Marine JC.

Nat Med. 2016 Aug;22(8):861-8. doi: 10.1038/nm.4135. Epub 2016 Jul 4.

PMID:
27376578
25.

Evaluation of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx) classification scheme for diagnosis of cutaneous melanocytic neoplasms: Results from the International Melanoma Pathology Study Group.

Lott JP, Elmore JG, Zhao GA, Knezevich SR, Frederick PD, Reisch LM, Chu EY, Cook MG, Duncan LM, Elenitsas R, Gerami P, Landman G, Lowe L, Messina JL, Mihm MC, van den Oord JJ, Rabkin MS, Schmidt B, Shea CR, Yun SJ, Xu GX, Piepkorn MW, Elder DE, Barnhill RL; International Melanoma Pathology Study Group.

J Am Acad Dermatol. 2016 Aug;75(2):356-63. doi: 10.1016/j.jaad.2016.04.052. Epub 2016 May 14.

26.

Melanoma addiction to the long non-coding RNA SAMMSON.

Leucci E, Vendramin R, Spinazzi M, Laurette P, Fiers M, Wouters J, Radaelli E, Eyckerman S, Leonelli C, Vanderheyden K, Rogiers A, Hermans E, Baatsen P, Aerts S, Amant F, Van Aelst S, van den Oord J, de Strooper B, Davidson I, Lafontaine DL, Gevaert K, Vandesompele J, Mestdagh P, Marine JC.

Nature. 2016 Mar 24;531(7595):518-22. doi: 10.1038/nature17161.

PMID:
27008969
27.

Transforming Growth Factor Beta Switch in Aqueous Humor of Patients With Fuchs' Endothelial Corneal Dystrophy.

De Roo AK, Struyf S, Foets B, van den Oord JJ.

Invest Ophthalmol Vis Sci. 2016 Feb;57(2):771-2. doi: 10.1167/iovs.15-18768. No abstract available.

PMID:
26927570
28.

Plasma cells in primary melanoma. Prognostic significance and possible role of IgA.

Bosisio FM, Wilmott JS, Volders N, Mercier M, Wouters J, Stas M, Blokx WA, Massi D, Thompson JF, Scolyer RA, van Baren N, van den Oord JJ.

Mod Pathol. 2016 Apr;29(4):347-58. doi: 10.1038/modpathol.2016.28. Epub 2016 Feb 12.

29.

Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study.

Cleynen I, Van Moerkercke W, Billiet T, Vandecandelaere P, Vande Casteele N, Breynaert C, Ballet V, Ferrante M, Noman M, Assche GV, Rutgeerts P, van den Oord JJ, Gils A, Segaert S, Vermeire S.

Ann Intern Med. 2016 Jan 5;164(1):10-22. doi: 10.7326/M15-0729. Epub 2015 Dec 8.

PMID:
26641955
30.

Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.

Boons E, Vanstreels E, Jacquemyn M, Nogueira TC, Neggers JE, Vercruysse T, van den Oord J, Tamir S, Shacham S, Landesman Y, Snoeck R, Pannecouque C, Andrei G, Daelemans D.

EBioMedicine. 2015 Aug 1;2(9):1102-13. doi: 10.1016/j.ebiom.2015.07.041. eCollection 2015 Sep.

31.

Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients.

Rogiers A, van den Oord JJ, Garmyn M, Stas M, Kenis C, Wildiers H, Marine JC, Wolter P.

Drugs Aging. 2015 Oct;32(10):821-34. doi: 10.1007/s40266-015-0304-7. Review.

PMID:
26442859
32.

First-in-Human Proof-of-Concept Study: Intralesional Administration of BQ788, an Endothelin Receptor B Antagonist, to Melanoma Skin Metastases.

Wouters J, Hunger RE, Garrod T, Dubuis B, Hunziker T, van den Oord JJ, Lahav-le Coutre R.

Oncologist. 2015 Oct;20(10):1121-2. doi: 10.1634/theoncologist.2015-0139. Epub 2015 Sep 1.

33.

Spontaneous Post-Transplant Disorders in NOD.Cg- Prkdcscid Il2rgtm1Sug/JicTac (NOG) Mice Engrafted with Patient-Derived Metastatic Melanomas.

Radaelli E, Hermans E, Omodho L, Francis A, Vander Borght S, Marine JC, van den Oord J, Amant F.

PLoS One. 2015 May 21;10(5):e0124974. doi: 10.1371/journal.pone.0124974. eCollection 2015.

34.

Prognostic Significance of Promoter Hypermethylation and Diminished Gene Expression of SYNPO2 in Melanoma.

Gao L, van den Hurk K, Nsengimana J, Laye JP, van den Oord JJ, Beck S, Gruis NA, Zoutman WH, van Engeland M, Newton-Bishop JA, Winnepenninckx VJ, van Doorn R.

J Invest Dermatol. 2015 Sep;135(9):2328-2331. doi: 10.1038/jid.2015.163. Epub 2015 Apr 28. No abstract available.

35.

Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort.

Nsengimana J, Laye J, Filia A, Walker C, Jewell R, Van den Oord JJ, Wolter P, Patel P, Sucker A, Schadendorf D, Jönsson GB, Bishop DT, Newton-Bishop J.

Oncotarget. 2015 May 10;6(13):11683-93.

36.

Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin.

Dudek-Perić AM, Ferreira GB, Muchowicz A, Wouters J, Prada N, Martin S, Kiviluoto S, Winiarska M, Boon L, Mathieu C, van den Oord J, Stas M, Gougeon ML, Golab J, Garg AD, Agostinis P.

Cancer Res. 2015 Apr 15;75(8):1603-14. doi: 10.1158/0008-5472.CAN-14-2089. Epub 2015 Mar 11.

37.

High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.

van den Hurk K, Balint B, Toomey S, O'Leary PC, Unwin L, Sheahan K, McDermott EW, Murphy I, van den Oord JJ, Rafferty M, FitzGerald DM, Moran J, Cummins R, MacEneaney O, Kay EW, O'Brien CP, Finn SP, Heffron CC, Murphy M, Yela R, Power DG, Regan PJ, McDermott CM, O'Keeffe A, Orosz Z, Donnellan PP, Crown JP, Hennessy BT, Gallagher WM.

Melanoma Res. 2015 Jun;25(3):189-99. doi: 10.1097/CMR.0000000000000149.

PMID:
25746038
38.

Mass Spectrometry of Flame Figures.

Wouters J, Waelkens E, Vandoninck S, Segaert S, van den Oord JJ.

Acta Derm Venereol. 2015 Jul;95(6):734-5. doi: 10.2340/00015555-2050. No abstract available.

39.

BRAFV600E immunopositive melanomas show low frequency of heterogeneity and association with epithelioid tumor cells: a STROBE-compliant article.

Verlinden I, van den Hurk K, Clarijs R, Willig AP, Stallinga CM, Roemen GM, van den Oord JJ, zur Hausen A, Speel EJ, Winnepenninckx VJ.

Medicine (Baltimore). 2014 Dec;93(28):e285. doi: 10.1097/MD.0000000000000285. Erratum in: Medicine (Baltimore). 2015 Apr;94(14):DOI: 10.1097/01.md.0000464339.19779.8f.

40.

MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.

Tuominen R, Jewell R, van den Oord JJ, Wolter P, Stierner U, Lindholm C, Hertzman Johansson C, Lindén D, Johansson H, Frostvik Stolt M, Walker C, Snowden H, Newton-Bishop J, Hansson J, Egyházi Brage S.

Int J Cancer. 2015 Jun 15;136(12):2844-53. doi: 10.1002/ijc.29332. Epub 2014 Nov 24.

41.

Tissue microarray.

Barrette K, van den Oord JJ, Garmyn M.

J Invest Dermatol. 2014 Sep;134(9):1-4. doi: 10.1038/jid.2014.277. No abstract available.

42.

A new and standardized method to sample and analyse vitreous samples by the Cellient automated cell block system.

Van Ginderdeuren R, Van Calster J, Stalmans P, Van den Oord J.

Acta Ophthalmol. 2014 Aug;92(5):e388-92. doi: 10.1111/aos.12360. Epub 2014 Feb 7.

43.

Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy.

Gao L, van den Hurk K, Moerkerk PTM, Goeman JJ, Beck S, Gruis NA, van den Oord JJ, Winnepenninckx VJ, van Engeland M, van Doorn R.

J Invest Dermatol. 2014 Dec;134(12):2957-2966. doi: 10.1038/jid.2014.270. Epub 2014 Jul 7.

44.

Antiherpesvirus activities of two novel 4'-thiothymidine derivatives, KAY-2-41 and KAH-39-149, are dependent on viral and cellular thymidine kinases.

Coen N, Duraffour S, Haraguchi K, Balzarini J, van den Oord JJ, Snoeck R, Andrei G.

Antimicrob Agents Chemother. 2014 Aug;58(8):4328-40. doi: 10.1128/AAC.02825-14. Epub 2014 May 12.

45.

Clinical presentation, pathological features and natural course of metastatic uveal melanoma, an orphan and commonly fatal disease.

Cerbone L, Van Ginderdeuren R, Van den Oord J, Fieuws S, Spileers W, Van Eenoo L, Wozniak A, Sternberg CN, Schöffski P.

Oncology. 2014;86(3):185-9. doi: 10.1159/000358729. Epub 2014 Apr 23.

PMID:
24776955
46.

Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression.

Denecker G, Vandamme N, Akay O, Koludrovic D, Taminau J, Lemeire K, Gheldof A, De Craene B, Van Gele M, Brochez L, Udupi GM, Rafferty M, Balint B, Gallagher WM, Ghanem G, Huylebroeck D, Haigh J, van den Oord J, Larue L, Davidson I, Marine JC, Berx G.

Cell Death Differ. 2014 Aug;21(8):1250-61. doi: 10.1038/cdd.2014.44. Epub 2014 Apr 25.

47.

Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.

Vanneste L, Wolter P, Van den Oord JJ, Stas M, Garmyn M.

J Eur Acad Dermatol Venereol. 2015 Jan;29(1):61-8. doi: 10.1111/jdv.12449. Epub 2014 Mar 24.

PMID:
24661317
48.

Epithelial-mesenchymal transition during invasion of cutaneous squamous cell carcinoma is paralleled by AKT activation.

Barrette K, Van Kelst S, Wouters J, Marasigan V, Fieuws S, Agostinis P, van den Oord J, Garmyn M.

Br J Dermatol. 2014 Nov;171(5):1014-21. doi: 10.1111/bjd.12967. Epub 2014 Oct 6.

PMID:
24628329
49.

Inherited variation in the PARP1 gene and survival from melanoma.

Davies JR, Jewell R, Affleck P, Anic GM, Randerson-Moor J, Ozola A, Egan KM, Elliott F, García-Casado Z, Hansson J, Harland M, Höiom V, Jian G, Jönsson G, Kumar R, Nagore E, Wendt J, Olsson H, Park JY, Patel P, Pjanova D, Puig S, Schadendorf D, Sivaramakrishna Rachakonda P, Snowden H, Stratigos AJ, Bafaloukos D, Ogbah Z, Sucker A, Van den Oord JJ, Van Doorn R, Walker C, Okamoto I, Wolter P, Barrett JH, Timothy Bishop D, Newton-Bishop J.

Int J Cancer. 2014 Oct 1;135(7):1625-33. doi: 10.1002/ijc.28796. Epub 2014 Mar 6.

50.

A novel hypoxia-associated subset of FN1 high MITF low melanoma cells: identification, characterization, and prognostic value.

Wouters J, Stas M, Govaere O, Barrette K, Dudek A, Vankelecom H, Haydu LE, Thompson JF, Scolyer RA, van den Oord JJ.

Mod Pathol. 2014 Aug;27(8):1088-100. doi: 10.1038/modpathol.2013.228. Epub 2014 Jan 3.

Supplemental Content

Loading ...
Support Center